FGF21 and metabolic disease: For example, the presented data of treatment with FGF-21 agonists or FGF-19 antibodies or analogues showed the great potential for their use in metabolic diseases, such as obesity, through beneficial effects on IS, lipid levels or food intake (Table 1).